<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04693169</url>
  </required_header>
  <id_info>
    <org_study_id>2020KT154</org_study_id>
    <nct_id>NCT04693169</nct_id>
  </id_info>
  <brief_title>[Al18F]PSMA137 PET/CT Imaging for PSMA-Positive Cancer Patients</brief_title>
  <official_title>[Al18F]PSMA137 PET/CT Imaging for PSMA-Positive Cancer Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Beijing Cancer Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Beijing Cancer Hospital</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      To investigate the radioactive uptake of [Al 18 F]PSMA137 in PCa patients, and evaluate the&#xD;
      ability of [Al 18 F]PSMA137 to detect PSMA overexpression in PCa patients (especially those&#xD;
      with recurrent or advanced PCa).To provide an approach for screening patients high expression&#xD;
      of PSMA, efficacy monitoring, drug resistance and early warning of recurrence and metastasis&#xD;
      to achieve the individualized antitumor treatment of targeted drugs.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Prostate cancer (PCa) is the most common malignant tumor in the male reproductive system, and&#xD;
      its prognosis and treatment mainly depend on the discovery of the primary disease and the&#xD;
      early stage of metastasis, while traditional imaging and histological methods are difficult&#xD;
      to meet the clinical requirements for the early diagnosis and accurate staging of&#xD;
      PCa.Positron emission tomography (PET) has the characteristics of precision and non-invasive,&#xD;
      so the development of PCa targeted molecular probe is of great significance for improving the&#xD;
      specificity and accuracy of PCa diagnosis.&#xD;
&#xD;
      PSMA is a highly specific prostatic epithelial membrane antigen, which is highly expressed in&#xD;
      solid tumors such as Prostate cancer. More than 90% of Prostate cancer cells express PSMA, so&#xD;
      PSMA can be used as an important imaging target for Prostate cancer.&#xD;
&#xD;
      The radionuclides used for PET imaging include 18F (T 1/2 =109.8min), which has a suitable&#xD;
      half-life and cyclotron preparation to enable the high yield synthesis of 18F labeled tracer,&#xD;
      so it can be used in more patients and provided to other departments without on-site tracer&#xD;
      production facilities.In addition, coordination labeling method is simple, easy to realize&#xD;
      automatic synthesis technology and medicine box preparation.Therefore, 18F-labeled PSMA&#xD;
      targeted molecular probe is a hot spot in the diagnosis of prostate cancer.&#xD;
&#xD;
      [Al18F]PSMA137 is a novel PSMA targeted tracer labeled with 18F. NOTA is used as a&#xD;
      bifunctional chelating agent to facilitate better chelation with Al18F. It has a higher tumor&#xD;
      uptake and a faster metabolism in normal organs with a lower background.[Al18F]PSMA137, as a&#xD;
      novel targeted molecular probe, shows excellent properties in tumor cell uptake.This project&#xD;
      provides research on [Al18F]PSMA137 PET/CT imaging for patients with suspected PCa, and&#xD;
      provides basis for early diagnosis of PCa, formulation of treatment plan and efficacy&#xD;
      evaluation.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 15, 2021</start_date>
  <completion_date type="Anticipated">December 12, 2023</completion_date>
  <primary_completion_date type="Anticipated">December 12, 2023</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>SUV（standardized uptake value）</measure>
    <time_frame>2 years</time_frame>
    <description>SUV is a semi-quantitative analysis index to describe the radioactive uptake of lesions, which has certain reference value for differentiating benign and malignant lesions。 The uptake of the tracer （[Al18F]PSMA137） in the primary and metastatic tumor lesions by measuring SUV on PET/CT</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">20</enrollment>
  <condition>Prostate Cancer</condition>
  <arm_group>
    <arm_group_label>[Al18F]PSMA137 PET/CT imaging</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>All study participants will be allocated to this arm (single-arm study).Study participants will undergo [Al18F]PSMA137 PET/CT scans.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>11C-Choline</intervention_name>
    <description>1、PSMA137 labeled with [Al18F] will be used as a molecular imaging tracer for PET/CT scanning。 2、11C-choline (0.05-0.1mCi/kg) was injected intravenously in a week after the [Al18F]PSMA137 PET/CT examination, and imaging of the head and body cadres was performed 20 min after the injection using Philips Gemini TF16 or Siemens Biograph M-CT flow PET/CT</description>
    <arm_group_label>[Al18F]PSMA137 PET/CT imaging</arm_group_label>
    <other_name>11C-CH</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Men over 18 years of age need to undergo [Al18F]PSMA137 PET/CT examination for&#xD;
             suspected prostate cancer.&#xD;
&#xD;
          -  The patients can fully understand and voluntarily participate in this experiment, and&#xD;
             sign the informed consent.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Significant hepatic or renal dysfunction;&#xD;
&#xD;
          -  Patients with malignant tumors other than prostate cancer within 2 years;&#xD;
&#xD;
          -  Ready to pregnant;&#xD;
&#xD;
          -  The patient can not tolerate all clinical tests.&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>90 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Yanan Ren</last_name>
    <phone>010-88196495</phone>
    <email>yananren123@126.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Hua Zhu, Associate Professor</last_name>
    <phone>010-88196495</phone>
    <email>zhuhuabch@pku.edu.cn</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Beijing Cancer Hospital</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>100142</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Teli Liu</last_name>
      <phone>010-88196196</phone>
      <email>liuteli123321@163.com</email>
    </contact>
    <contact_backup>
      <last_name>Yanan Ren</last_name>
      <phone>010-88196196</phone>
      <email>yananren123@126.com</email>
    </contact_backup>
    <investigator>
      <last_name>Zhi Yang</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>January 2021</verification_date>
  <study_first_submitted>December 30, 2020</study_first_submitted>
  <study_first_submitted_qc>December 30, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">January 5, 2021</study_first_posted>
  <last_update_submitted>January 15, 2021</last_update_submitted>
  <last_update_submitted_qc>January 15, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">January 19, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Beijing Cancer Hospital</investigator_affiliation>
    <investigator_full_name>Hua Zhu</investigator_full_name>
    <investigator_title>Associate Professor</investigator_title>
  </responsible_party>
  <keyword>PSMA</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prostatic Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Choline</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

